<DOC>
	<DOCNO>NCT00496756</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study side effect well sorafenib work treat patient metastatic unresectable kidney cancer .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Metastatic Unresectable Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate safety toxicity dose escalate sorafenib tosylate patient metastatic unresectable renal cell carcinoma . Secondary - Determine tumor response patient . - Determine time progression patient . - Determine overall survival patient . Tertiary - Collect data angiogenesis inhibition induce sorafenib tosylate . - Collect data immunomodulatory effect sorafenib tosylate . OUTLINE : This open-label study . Patients receive oral sorafenib tosylate twice daily day 1-28 . Treatment repeat every 4 week least 2 course absence disease progression unacceptable toxicity . Patients receive escalate dos sorafenib tosylate ( absence grade 3 4 dose-limiting toxicity ) pre-determined dose reach . Blood urine sample collect baseline periodically study VEGF level determination . Blood sample analyze T4/T8 , NK , CD25+ , Fox p3 flow cytometry . Tumor tissue block unstained slide obtain chemistry stain VEGF .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm renal cell carcinoma ( RCC ) Must component conventional clear cell RCC Predominant clear cell component ≥ 75 % Patients true papillary , sarcomatoid feature without clear cell component , chromophobe , oncocytoma , collect duct tumor , transitional cell carcinoma eligible Metastatic unresectable disease Measurable nonmeasurable disease Measurable disease define lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan MRI Nonmeasurable disease include follow : Small lesion long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonitis Abdominal mass confirm followed imaging technique Cystic lesion Irradiated lesion , unless progression document radiotherapy Paraffin RCC tissue block unstained slide must obtain future chemistry stain VEGF No evidence CNS metastases No imaging ( MRI CT scan brain ) abnormality indicative CNS metastasis within past 42 day PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( hormonal and/or barrier method ) 3 month completion study treatment Granulocyte count ≥ 1,500/µL Platelet count ≥ 100,000/µL AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Serum bilirubin ≤ 1.5 time ULN Protein ≤ 1+ urinalysis Creatinine ≤ 1.5 time ULN No ongoing hemoptysis No cerebrovascular accident within past 12 month No peripheral vascular disease claudication walk less 1 block No history clinically significant bleed No deep venous thrombosis pulmonary embolus within past year No significant cardiovascular disease , define NYHA class IIIV congestive heart failure , angina pectoris require nitrate therapy , myocardial infarction within past 6 month No uncontrolled hypertension , define systolic BP &gt; 160 mm Hg and/or diastolic BP &gt; 90 mm Hg medication No preexisting thyroid abnormality whose thyroid function maintain normal range medication No uncontrolled psychiatric disorder No delay heal wound , ulcer , and/or bone fracture No currently active second malignancy except nonmelanoma skin cancer Patients consider 'currently active ' malignancy complete anticancer therapy consider physician less 30 % risk relapse PRIOR CONCURRENT THERAPY : At least 4 week since prior major surgery and/or radiotherapy recover No one prior systemic therapy RCC No prior vascular endothelial growth factor receptor agent Prior palliative radiotherapy metastatic lesion ( ) allow provide least one measurable and/or evaluable lesion ( ) irradiate More 4 week since prior concurrent anticancer therapy Concurrent continuation bisphosphonates allow bone metastasis prophylaxis No concurrent systemic corticosteroid therapy ( except replacement therapy adrenal insufficiency ) Topical and/or inhale steroid allow No concurrent fulldose oral parenteral anticoagulation Lowdose warfarin ( 1 mg ) maintenance catheter patency daily prophylactic aspirin allow No concurrent Hypericum perforatum ( St. John 's wort ) No concurrent ketoconazole , itraconazole , ritonavir , rifampin , product contain grapefruit juice No concurrent hormonal therapy chemotherapy Concurrent hormone administer nondisease related condition ( e.g. , insulin diabetes ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>